News

Retatrutide FDA approval status: not approved as of July 2026. It's in Phase 3 trials, with an NDA expected and approval projected for 2027 at earliest.

GLOW is an informal multi-peptide skin rejuvenation stack — typically GHK-Cu, BPC-157, and TB-500. Here's what it is, the mechanism rationale, and how it compares to topical-only approaches.

KLOW is an informal research-community stack combining KPV, Larazotide, Orexin-related compounds, and Wolverine-stack peptides for combined gut, inflammation, sleep, and tissue support.

Cagrilintide (AM833) is Novo Nordisk's long-acting amylin receptor agonist. Combined with Semaglutide it produces ~17–22% weight loss in Phase 3 trials with a different mechanism than GLP-1.

Retatrutide (LY3437943) is a GLP-1 + GIP + glucagon triple receptor agonist producing ~24% weight loss at 48 weeks in Phase 2 trials. Here's what it is, how it works, and where it stands.

SLU-PP-332 is a synthetic pan-ERR agonist that mimics endurance-exercise gene expression in animal models. Here's what's actually known, what's speculative, and why caution is warranted.